XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2
In-license, Acquisition and Collaboration Agreements - Regeneron License Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 28, 2022
Sep. 30, 2017
Jun. 30, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
License and Acquisition Agreements                
Research and development     $ 13,798 $ 23,945   $ 34,615 $ 52,628  
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured   90 days            
Notice period to terminate the agreement under payment-related breaches   30 days            
Consecutive suspension of activities period for termination of agreement   12 months            
Notice period to terminate the agreement   1 year            
Notice period to terminate the agreement if products are having safety concerns   3 months            
Intangible asset - Regulatory milestone     20,000     20,000   $ 20,000
Commercial product inventory     19,916     19,916   3,675
Regulatory milestone                
License and Acquisition Agreements                
Intangible asset - Regulatory milestone     20,000     20,000   20,000
Regeneron | License Agreement                
License and Acquisition Agreements                
Regulatory milestone payment         $ 20,000      
Profit sharing recognized     3,672     11,926 $ 0  
Regeneron | License Agreement | Regulatory milestone                
License and Acquisition Agreements                
Intangible asset - Regulatory milestone     20,000     20,000    
Regeneron | License Agreement | Short-term liabilities                
License and Acquisition Agreements                
Profit sharing recognized $ 6,000              
Regeneron | Clinical Supply Agreement                
License and Acquisition Agreements                
Commercial product inventory     $ 19,916     $ 19,916   $ 3,675